Orgenesis (NASDAQ:ORGS) Shares Down 16.7% – Should You Sell?

Orgenesis Inc. (NASDAQ:ORGSGet Free Report) was down 16.7% during trading on Friday . The stock traded as low as $0.25 and last traded at $0.25. Approximately 100 shares changed hands during trading, a decline of 86% from the average daily volume of 705 shares. The stock had previously closed at $0.30.

Orgenesis Price Performance

The stock has a fifty day simple moving average of $0.41 and a two-hundred day simple moving average of $0.40. The firm has a market capitalization of $1.29 million, a P/E ratio of -0.04 and a beta of 3.76.

About Orgenesis

(Get Free Report)

Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.

The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.

Featured Stories

Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.